Docoh
Loading...

AZN Astrazeneca

News

Pro users get this 30m faster
'FDA slaps clinical hold on AstraZeneca cancer drug amid heart safety scare in combo test' -Earlier Article From Fierce Biotech
20 Oct 21
News, Rumors, Movers, Media, Trading Ideas
https://www.fiercebiotech.com/biotech/fda-slaps-clinical-hold-astrazeneca-cancer-drug-amid-heart-safety-scare-combo-test
AstraZeneca Pulls Plug On MCL-1 Cancer Drug Trial
20 Oct 21
Biotech, News, Health Care, General
AstraZeneca Plc (NASDAQ: AZN) has paused an active Phase 1 trial of AZD5991, a direct inhibitor of MCL-1, citing a potential safety issue.
Novavax Shares Plunge To Lowest Levels Since Mid-May As COVID-19 Vaccine Woes Continue
20 Oct 21
Biotech, News, Health Care, Movers, Trading Ideas, General
Shares of Novavax, Inc. (NASDAQ: NVAX), which is facing an inordinate delay in getting authorization for its
Oxford Vaccine Head Said Delta Subvariant Unlikely to Change Covid Situation Dramatically
20 Oct 21
News
-Reuters https://www.reuters.com/world/uk/delta-subvariant-wont-change-covid-picture-oxford-vaccine-chief-says-2021-10-20/
AstraZeneca, Unilever Tumble As FTSE 100 Struggles With Rising Energy Prices
19 Oct 21
News
Shares of COVID-19 vaccine maker AstraZeneca PLC (NASDAQ: AZN) along with other multinational British companies such as Unilever PLC (NYSE: UL), Diageo PLC (NYSE:
Earnings Season Continues with State Street, Albertsons, and Sandvik Announcing on Monday Morning
18 Oct 21
Earnings, Government, News, Regulations, Health Care, Futures, Commodities, Retail Sales, Small Cap, Global, Markets, General
Stocks appear to be pausing as rates start to rise. Before the U.S. markets opened, short-term U.S. Treasury yields were rising. The five-year yields rose to their highest levels in 20 months per Reuters.
Why Are Valneva's Shares Trading Higher Monday Premarket?
18 Oct 21
Biotech, Long Ideas, News, Health Care, Small Cap, Movers, Trading Ideas, General
The Daily Biotech Pulse: Moderna's Booster Shot Gets FDA Panel Backing, Decision Day For Avadel, Silence Therapeutics Strikes Licensing Deal, MiNK IPO
15 Oct 21
Biotech, News, Small Cap, FDA, IPOs, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
AstraZeneca Announced Himalaya Phase III Trial Met Primary Endpoint of Survival in 1st-line Unresectable Liver Cancer
15 Oct 21
News
Positive high-level results from the HIMALAYA Phase III trial showed a single, high priming dose of tremelimumab added to Imfinzi (durvalumab) demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit versus sorafenib as a 1st-line treatment for patients with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy and were not
AstraZeneca Covid-19 Vaccine Will No Longer Be Made in Australia Due to Demand for Pfizer, Moderna Vaccines
13 Oct 21
News
-9 News https://www.9news.com.au/national/coronavirus-update-astrazeneca-vaccine-will-no-longer-be-manufactured-in-australia/17980617-f2b1-4426-b1d7-46019ab1847a
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
12 Oct 21
Biotech, Earnings, News, Penny Stocks, Offerings, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11)
AstraZeneca's COVID-19 Therapy Hits Goal In Phase 3 Trial
11 Oct 21
Biotech, News, Health Care, General
AstraZeneca Plc (NASDAQ: AZN) released
'Russian spies 'stole formula for Oxford/Astra Zeneca Covid jab and used it to create Sputnik vaccine'' - The Sun
11 Oct 21
News, Global
https://www.thesun.co.uk/news/16381674/russia-stole-formula-oxfords-covid-jab/
AstraZeneca Announced AZD7442 Reduced Risk of Developing Severe Covid-19 or Death in TACKLE Phase III Outpatient Treatment Trial; Trial Met Primary Endpoint
11 Oct 21
News
Positive high-level results from the TACKLE Phase III COVID-19 treatment trial showed AstraZeneca's AZD7442, a long acting antibody (LAAB) combination, achieved a statistically significant reduction in severe COVID-19 or death compared to placebo in non-hospitalised patients with mild-to-moderate symptomatic COVID-19.
Why New COVID-19 Vaccination-Related Rules In This Australian State Have Small Businesses Worried
11 Oct 21
News, Global
With the state of New South Wales, including capital Sydney, officially marking an end to its 106-day lockdown, certain small business owners have decided to remain closed, with restaurants only offering takeaway services.
AstraZeneca Reports Tezepelumab Granted Orphan Drug Designation In US For Eosinophilic Esophagitis
8 Oct 21
Biotech, News, FDA, General
Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE). Tezepelumab is being developed by AstraZeneca in
AstraZeneca's Debt Overview
7 Oct 21
News, Intraday Update, Markets
Shares of AstraZeneca (NASDAQ:AZN) moved lower by 1.12% in the past three months. Before having a look at the importance of debt, let us look at how much debt AstraZeneca has.
AstraZeneca Granted Orphan Designation For Tezepelumab
7 Oct 21
News, FDA
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=839721
Best Crypto PR Agencies You Must Know
6 Oct 21
Cryptocurrency
Public relations is the lifeblood of any industry. Companies, service providers, and developers need to make the audience aware of what they bring to the table. Numerous PR agencies provide a compelling service in the crypto and blockchain world, however, few have the experienced team and network to make a crypto project shine.
AstraZeneca Seeks Emergency Use Nod For COVID-19 Drug To Prevent Infection
5 Oct 21
Biotech, News, Health Care, General

Press releases

Pro users get this 30m faster
Imfinzi plus tremelimumab significantly improved overall survival in HIMALAYA Phase III trial in 1st-line unresectable liver cancer
15 Oct 21
News, Press Releases
Positive high-level results from the HIMALAYA Phase III trial showed a single, high priming dose of tremelimumab added to Imfinzi (durvalumab) demonstrated a statistically significant and clinically meaningful overall
IMFINZI Plus Tremelimumab Significantly Improved Overall Survival in HIMALAYA Phase III Trial in 1st-Line Unresectable Liver Cancer
15 Oct 21
Press Releases
Trial met primary endpoint of overall survival with a single priming dose of tremelimumab plus IMFINZI every four weeks vs. sorafenib IMFINZI monotherapy met the overall survival endpoint of non-inferiority vs.
Tezepelumab granted Orphan Drug Designation in the US for eosinophilic esophagitis
8 Oct 21
Press Releases
Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE). Tezepelumab is being developed by AstraZeneca in
Thinking about buying stock in Bit Digital, BP, Marathon Digital, AstraZeneca, or Norwegian Cruise Line?
6 Oct 21
Opinion, Press Releases
NEW YORK, Oct. 6, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BTBT, BP, MARA, AZN, and NCLH.
AZD7442 Request for Emergency Use Authorization for COVID-19 Prophylaxis Filed in US
5 Oct 21
Press Releases
Filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic COVID-19 with long-acting antibody combination (non-vaccine) Potential to provide protection for those not
AZD7442 request for Emergency Use Authorization for COVID-19 prophylaxis filed in US
5 Oct 21
News, Press Releases
AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) combination, for prophylaxis of symptomatic
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Granted Breakthrough Therapy Designation in US for Patients with HER2-Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based Regimens
4 Oct 21
Press Releases
Based on ground-breaking DESTINY-Breast03 trial results where ENHERTU reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) ENHERTU has now been granted four Breakthrough Therapy
Compugen Announces Milestone Payment from AstraZeneca Triggered by First Patient Dosed with TIGIT Bispecific Derived from COM902
4 Oct 21
Press Releases
HOLON, Israel, Oct. 4, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that Compugen is entitled to receive a
Thinking about trading options or stock in Dollar Tree, Asana, AstraZeneca, Moderna, or Winnebago?
29 Sep 21
Opinion, Press Releases
NEW YORK, Sept. 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DLTR, ASAN, AZN, MRNA, and WGO.
AstraZeneca Healthcare Foundation Awards Seven US Nonprofits More Than $900k to Improve Heart Health and Advance Health Equity
29 Sep 21
Press Releases
Today on World Heart Day, the AstraZeneca HealthCare Foundation has awarded seven innovative, community-based nonprofit organizations $954,311 in grants across seven US states to address cardiovascular disease, a
AstraZeneca COVID-19 and RSV presentations at IDWeek 2021 will showcase scientific progress in infectious diseases
27 Sep 21
Press Releases
AZD7442 long-acting antibody combination Phase III PROVENT trial prevention data to be presented in late-breaker session AZD1222 Phase III analysis investigating asymptomatic infection and duration of viral shedding in
Thinking about trading options or stock in AstraZeneca, Microsoft, Walt Disney, Alibaba, or Moderna?
24 Sep 21
Opinion, Press Releases
NEW YORK, Sept. 24, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AZN, MSFT, DIS, BABA, and MRNA.
LYNPARZA® (olaparib) in combination with abiraterone significantly delayed disease progression in all-comers in PROpel Phase III trial in 1st-line metastatic castration-resistant prostate cancer
24 Sep 21
Press Releases
First PARP inhibitor to demonstrate clinical benefit in combination with a new hormonal agent in this setting AstraZeneca and Merck & Co., Inc., known as MSD outside the US and Canada, today announced positive
Rare Adverse Effects Continue to Fuel Covid-19 Vaccine Hesitancy, Despite Safety Breakthroughs
23 Sep 21
Small Cap, Opinion, Press Releases
VANCOUVER, BC, Sept. 23, 2021 /PRNewswire/ -- USA News Group - Despite the approval for the Comirnaty vaccine from Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) by the FDA back in August, vaccine hesitancy in
AstraZeneca to invest $360m in advanced manufacturing facility in Ireland
21 Sep 21
News, Press Releases
AstraZeneca is planning on establishing a next-generation active pharmaceutical ingredient (API) manufacturing facility for small molecules near Dublin, Ireland to ensure the Company's global supply network is fit
IMFINZI Plus Chemotherapy Tripled Patient Survival at Three Years in the CASPIAN Phase III Trial in Extensive-Stage Small Cell Lung Cancer
18 Sep 21
Press Releases
Longest survival follow-up ever reported for immunotherapy treatment in this setting Updated results from the CASPIAN Phase III trial showed AstraZeneca's IMFINZI® (durvalumab) in combination with a choice of
IMFINZI plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial in extensive-stage small cell lung cancer
18 Sep 21
Press Releases
Longest survival follow-up ever reported for immunotherapy treatment in this setting Updated results from the CASPIAN Phase III trial showed AstraZeneca's IMFINZI® (durvalumab) in combination with a choice of
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
18 Sep 21
Press Releases
Ground-breaking Phase III head-to-head DESTINY-Breast03 results featured at ESMO Presidential Symposium support ENHERTU as the potential new standard of care in previously treated patients DESTINY-Breast01 Phase II
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated robust and durable tumor response of 54.9% in patients with HER2-mutant metastatic non-small cell lung cancer
18 Sep 21
Press Releases
First HER2-directed therapy to show a strong tumor response in this population Data from HER2-mutant cohort of pivotal DESTINY-Lung01 Phase II trial presented at ESMO and published in The New England Journal of
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable response in patients with HER2-positive advanced gastric cancer in DESTINY-Gastric02 Phase II trial
17 Sep 21
Press Releases
First ENHERTU trial in Western patients with gastric cancer Efficacy and safety results consistent with registrational DESTINY-Gastric01 will support ongoing discussions with global health authorities Detailed results